NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”), a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced the pricing of its initial public offering of 174,286 ordinary shares at a public offering price of $20.00 per share. BeyondSpring also announced the sale of an aggregate of 2,541,048 ordinary shares at $20.00 per share, in a concurrent private placement transaction. The gross proceeds from the initial public offering and the private placement are expected to be $54.31 million, before deducting underwriting discounts and commissions and other offering expenses. The underwriters have a 30-day option to purchase from BeyondSpring up to an additional 26,141 ordinary shares in the public offering. The ordinary shares sold in the public offering are expected to commence trading on The NASDAQ Capital Market on March 9, 2017 under the ticker symbol “ BYSI .” The offerings are expected to close on or about March 14, 2016, subject to satisfaction of customary closing conditions.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as the sole bookrunner for the public offering and acted as the exclusive placement agent for the concurrent private placement.
The offering of these securities in the public offering will be made only by means of a written prospectus. A copy of the prospectus related to the offering may be obtained from Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC if requested by email at placements@hcwco.com or by phone at 646-975-6957.
A registration statement relating to the securities being sold in the public offering has been filed with, and was declared effective by, the U.S. Securities and Exchange Commission.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described above nor shall there be any sale of the securities described above in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About BeyondSpring BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Certain of the statements made in this press release are forward looking, such as those, among others, relating to BeyondSpring’s expectations regarding the completion of the proposed public offering and the concurrent private placement. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the anticipated amount needed to finance the company's future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Company Contact: Richard Brand BeyondSpring Chief Financial Officer 201.577.8221, rbrand@beyondspringpharma.com
